China Regenerative Medicine Intl : R&D Team of “Acornea” Invited to Share the R&D and Application Experience of the First Chinese Bio- engineered Cornea at Oxford

[Group News] China Regenerative Medicine International Limited (Stock Code: 8158.HK) R&D Team of "Acornea" Invited to Share the R&D and Application Experience of the First Chinese Bio- engineered Cornea at Oxford

Hong Kong, 12 Aug 2017 - China Regenerative Medicine International Limited ("China Regenerative Medicine" or "the Company", stock code: 8158.HK, together with its subsidiaries collectively "the Group") is pleased to announce that the Group's R&D team of bio-engineered cornea product -"Acornea" gave a keynote presentation titled "new type of bio-engineered cornea R&D and clinical applications" at the world's top university - Oxford, at the invitation of Prof. Zhanfeng Cui, who is the first Chinese statutory Chair in the Oxford University and a Fellow of the Royal Academy of Engineering (FREng), and had active discussion and exchange with scholars from all over the world.

R&D team of "Acornea" is giving a keynote presentation at the workshop

Prof. Zhanfeng Cui, Fellow of the Royal Academy of Engineering (FREng), said, "The R&D team of "Acornea" has made significant contributions to the leapfrog development of bio-engineered cornea, and expect to further the development on tissue engineering in ophthalmic repair in the future." Prof. Weiyun Shi, the director of Shandong Ophthalmologic Research Institute, president of Shandong Eye Hospital, a standing committee member of Chinese Ophthalmological Society as well as the leader of the Corneal Pathology Group, and a number of experts from Shandong Eye Institute delivered the keynote speech, had in-depth exchange with scholars from all over the world on bio-engineered cornea. Prof. Shi is again recognized by the world's top university to send out voice of China to the world, on behalf of Chinese ophthalmic sector, following his speech at Massachusetts General Hospital at the invitation of the MGH Chinese Scientist and Staff Association (CSSA) of Harvard University in the U.S. in October 2016.

- End -

About China Regenerative Medicine International Limited

China Regenerative Medicine International Limited, listed on the GEM Board of The Stock Exchange, stock code :8158. China Regenerative Medicine is a high-end new- technology enterprise, principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The Group has accomplished the research and development and commercialization platform of tissue engineering and applied for more than 140 domestic and overseas patents on three major business segments, namely tissue engineering, cell therapy and cosmetics, including 'ActivSkin', the only tissue-engineered skin developed in China, and 'Acornea', the world's first bio-engineered cornea which completed its clinical trials. For more details, please visit www.crmi.hk